Subscribe
shutterstock_1533140117_michael_vi
Michael Vi / Shutterstock.com
22 August 2023Big PharmaMuireann Bolger and Sarah Speight

UPC confirms dates for 10x Genomics hearings

UPC announces public hearings at Munich court | Proceedings relate to the dispute over patents covering the in-situ detection of analytes.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
10x Genomics 'overjoyed' to win UPC preliminary injunction
19 September 2023   Decision marks first announcement by the UPC of an injunction in open court | Ruling in Munich Local Division forecast to have far-reaching consequences for defendant| Comment from 10x vice president of IP and litigation, Randy Wu.
Big Pharma
UPC after one month: Life sciences cases
29 June 2023   Revocation and infringement actions involving a cholesterol treatment, prosthetic valves, and methods for analyte detection are among the first to land at the court within its first month, explain Joanne Welch and Darren Smyth of EIP.
Big Pharma
Sanofi v Amgen antibody case lands front of queue at UPC
6 June 2023   Big pharma company picks pan-European venue for next leg of global dispute | IT issues potentially behind new court's low revocation count | Nearly half a million opt-outs registered.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Biotechnology
10x Genomics 'overjoyed' to win UPC preliminary injunction
19 September 2023   Decision marks first announcement by the UPC of an injunction in open court | Ruling in Munich Local Division forecast to have far-reaching consequences for defendant| Comment from 10x vice president of IP and litigation, Randy Wu.
Big Pharma
UPC after one month: Life sciences cases
29 June 2023   Revocation and infringement actions involving a cholesterol treatment, prosthetic valves, and methods for analyte detection are among the first to land at the court within its first month, explain Joanne Welch and Darren Smyth of EIP.
Big Pharma
Sanofi v Amgen antibody case lands front of queue at UPC
6 June 2023   Big pharma company picks pan-European venue for next leg of global dispute | IT issues potentially behind new court's low revocation count | Nearly half a million opt-outs registered.

More on this story

Biotechnology
10x Genomics 'overjoyed' to win UPC preliminary injunction
19 September 2023   Decision marks first announcement by the UPC of an injunction in open court | Ruling in Munich Local Division forecast to have far-reaching consequences for defendant| Comment from 10x vice president of IP and litigation, Randy Wu.
Big Pharma
UPC after one month: Life sciences cases
29 June 2023   Revocation and infringement actions involving a cholesterol treatment, prosthetic valves, and methods for analyte detection are among the first to land at the court within its first month, explain Joanne Welch and Darren Smyth of EIP.
Big Pharma
Sanofi v Amgen antibody case lands front of queue at UPC
6 June 2023   Big pharma company picks pan-European venue for next leg of global dispute | IT issues potentially behind new court's low revocation count | Nearly half a million opt-outs registered.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB